In this brief explanation, the speaker outlines how hyperbaric oxygen therapy (HBOT) increases oxygen delivery to deep tissue beds, which in turn alters the expression of hypoxia‑inducible factor (HIF) and vascular endothelial growth factor (VEGF). These molecular shifts are presented as moving the body toward a state that confers anti‑cancer effects, suggesting that HBOT may help inhibit tumor growth by modulating pathways linked to hypoxia and angiogenesis.
So what happens is that when you do hyperbaric oxygen, there's a number of things that occur. And one of the primary things is, is that the tissue beds, so the deeper tissues in the body, get perfused with more oxygen, which of course hyperbaric would probably do that. The things that happen then is more oxygen actually changes the levels of hypoxia induction factor and VEGF, vascular endothelial growth factor, and a number of other things. And it changes them in a direction where we get all these positive anti-cancer benefits. So when we shift HIF and VEGF, we get a change in a number of factors that go on.
